| 產(chǎn)品編號(hào) | bs-0740R |
| 英文名稱 | CDKN2A/p16-INK4a Rabbit pAb |
| 中文名稱 | 抑癌基因p16抗體 |
| 別 名 | cyclin-dependent kinase inhibitor 2A; CDK4I; p16-INK4; p16-INK4a; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A, isoform 1; Cyclin dependent kinase inhibitor 2A(p16, inhibits CDK4); cell cycle inhibitor; cyclin-dependent kina |
 |
Specific References (5) | bs-0740R has been referenced in 5 publications.
[IF=11.161] Cui Yuanbo. et al. RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma. J Exp Clin Canc Res. 2021 Dec;40(1):1-20 WB ; human.
[IF=7.31] Zhiheng Liao. et al. Dihydroartemisinin Attenuated Intervertebral Disc Degeneration via Inhibiting PI3K/AKT and NF-κB Signaling Pathways.. OXID MED CELL LONGEV. 2022 Sep;2022:8672969-8672969 IHC ; Rat.
[IF=7.068] Cao M et al. Interplay between cancer cells and M2 macrophages is necessary for miR-550a-3-5p down-regulation-mediated HPV-positive OSCC progression. J Exp Clin Cancer Res. 2020 Jun 3;39(1):102. IHC-P ; Human.
[IF=4.996] Jiang Jie. et al. Artificial intelligence reveals dysregulation of osteosarcoma and cuproptosis-related biomarkers, PDHA1, CDKN2A and neutrophils. SCI REP-UK. 2023 Mar;13(1):1-16 IHC ; Human.
[IF=4.92] Carreras et al. Chronic sleep fragmentation induces endothelial dysfunction and structural vascular changes in mice. (2014) Slee. 37:1817-24 IHC-P ; Mouse.
|
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 染色質(zhì)和核信號(hào) 信號(hào)轉(zhuǎn)導(dǎo) 干細(xì)胞 細(xì)胞周期蛋白 轉(zhuǎn)錄調(diào)節(jié)因子 |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 17 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human p16-INK4a: 61-156/156 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]. Function: Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. Subunit: Heterodimer with CDK4 or CDK6. Predominant p16 complexes contained CDK6. Interacts (isoforms 1,2 and 4) with CDK4 (both 'T-172'-phosphorylated and non-phosphorylated forms); the interaction inhibits cyclin D-CDK4 kinase activity. Interacts with ISCO2. Subcellular Location: Cytoplasm. Nucleus. Tissue Specificity: Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific. DISEASE: Note=The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients. Defects in CDKN2A are the cause of cutaneous malignant melanoma type 2 (CMM2) [MIM:155601]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719]. Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. [DISEASE] Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome (MASTS) [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Similarity: Belongs to the CDKN2 cyclin-dependent kinase inhibitor family. Contains 4 ANK repeats. SWISS: P42771 Gene ID: 1029 Database links: Entrez Gene: 1029 Human Entrez Gene: 12578 Mouse Omim: 600160 Human SwissProt: P42771 Human SwissProt: P51480 Mouse Unigene: 512599 Human Unigene: 4733 Mouse Unigene: 48717 Rat 細(xì)胞周期失控是癌變的重要原因。p16是近年來(lái)發(fā)現(xiàn)的第一個(gè)直接參與細(xì)胞周期調(diào)控的抑癌基因，其表達(dá)產(chǎn)物為p16蛋白. p16基因是一種重要的抑癌基因，在正常細(xì)胞中起負(fù)反饋?zhàn)饔茫?dāng)p16基因突變或丟失時(shí)，細(xì)胞增殖失去控制使細(xì)胞無(wú)限制地增殖。 p16主要功能是通過(guò)抑制CDK4而阻止細(xì)胞由G1期進(jìn)入S期，使細(xì)胞增殖受到限制。用于各種惡性腫瘤如肺癌、惡黑、乳腺癌的研究。目前的研究細(xì)胞周期依賴激酶抑制p16INK4a蛋白在宮頸上皮內(nèi)病變(CIN)中作為一個(gè)新標(biāo)記物. p16INK4a的過(guò)表達(dá)與HPV E7區(qū)(病毒早期蛋白即病毒致癌基因編碼區(qū))活性有密切相關(guān)性。 p16/CDKN2基因是新近發(fā)現(xiàn)的腫瘤抑制基因，已有研究表明該基因在許多腫瘤出現(xiàn)缺失、突變或重排現(xiàn)象. |
| 產(chǎn)品圖片 |
Tissue/cell: human kidney tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-CDKN2A/p16-INK4a Polyclonal Antibody, Unconjugated(bs-0740R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
